Collegium Pharmaceutical (NASDAQ:COLL) versus NKGen Biotech (NYSE:NKGN) Financial Survey

NKGen Biotech (NYSE:NKGN) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Insider and Institutional Ownership

76.2% of NKGen Biotech shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 1.8% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares NKGen Biotech and Collegium Pharmaceutical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94 million	($1.68)	-0.00
Collegium Pharmaceutical	$808.21 million	1.10	$62.87 million	$1.24	22.01

Collegium Pharmaceutical has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for NKGen Biotech and Collegium Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0	0	0	0	0.00
Collegium Pharmaceutical	0	3	3	1	2.71

Collegium Pharmaceutical has a consensus price target of $51.00, indicating a potential upside of 86.85%. Given Collegium Pharmaceutical’s stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than NKGen Biotech.

Profitability

This table compares NKGen Biotech and Collegium Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Volatility & Risk

NKGen Biotech has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Summary

Collegium Pharmaceutical beats NKGen Biotech on 11 of the 13 factors compared between the two stocks.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.